US Patent

US9120727 — Process for the preparation of pleuromutilins

Composition of Matter · Assigned to Nabriva Therapeutics AG · Expires 2031-05-23 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a process for preparing a compound of formula I, a single stereoisomer in crystalline form, through deprotection and isolation.

USPTO Abstract

Process for the preparation of a compound of formula I in the form of a single stereoisomer in crystalline form, comprising deprotecting the amine group in a compound of formula IIa or in a mixture of a compound of formula IIa with a compound of formula IIb and isolating a compound of formula I from the reaction mixture; compounds and salts of compounds of formula I in crystalline form; pharmaceutical compositions comprising such salts; processes for the preparation of intermediates and intermediates in a process for the preparation of a compound of formula I.

Drugs covered by this patent

Patent Metadata

Patent number
US9120727
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-05-23
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Nabriva Therapeutics AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.